MARIPOSA

NCT04487080 📎

Regimen

Experimental
amivantamab + lazertinib
Control
osimertinib

Population

Advanced EGFR-mut (del19/L858R) NSCLC 1L

Key finding

mPFS 23.7 vs 16.6 mo, HR 0.70 (0.58-0.85); ami+laz superior to osi in PFS

Source: PMID 38924756

Timeline

  • Enrollment start: 2020-09-30 📎

Guideline citations

  • NCCN NSCLC Version 5.2026 (p.112)
  • CSCO NSCLC 2025 ⚠️ OCR source